Kyprolis is a proteasome inhibitor that blocks the activity of enzyme complexes called proteasomes, which are important for maintaining balance within the cell and for regulating cell growth. Kyprolis is given by intravenous (IV) infusion.
Indication for the use of Kyprolis
Kyprolis was originally approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of adult patients with myeloma who have received at least 2 prior therapies, including a proteasome inhibitor and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Kyprolis is FDA-approved for relapsed or refractory myeloma in the following settings:
¡ Kyprolis as a single agent after 1 or more prior lines of therapy.
¡ Kyprolis + dexamethasone (Kd) after 1 to 3 prior lines of therapy.
¡ Kyprolis + Revlimid® (lenalidomide) + dexamethasone (KRd) after 1 to 3 prior lines of therapy.
¡ Kyprolis + Darzalex® (daratumumab) + dexamethasone (DKd) after 1 to 3 prior lines of therapy. Alternatively, Darzalex Faspro® (daratumumab + hyaluronidase-fihj), a newer formulation of Darzalex, may be used in DKd.
¡ Kyprolis + Sarclisa® (isatuximab-irfc) + dexamethasone (Isa-Kd) after 1 to 3 prior lines of therapy.
International Myeloma
Foundation
4400 Coldwater Canyon Avenue #300 – Studio City, CA 91604
1.818.487.7455 TheIMF@myeloma.org myeloma.org
Precautions with the use of Kyprolis
Prior to your treatment with Kyprolis, talk with your doctor about the following:
¡ Pretreatment with dexamethasone,
¡ How much water you should drink,
¡ Medication to prevent blood clots,
¡ Antiviral therapy to decrease the risk of shingles, and
¡ Special cautions for females of reproductive potential. Patients are monitored carefully for infusion-related reactions (IRR), which can occur immediately following an infusion or in the days after. Complications may include fever, chills, joint pain, muscle pain, facial flushing, facial swelling, vomiting, weakness, shortness of breath, low blood pressure, fainting, chest tightness, or chest pain.
Serious side effects of Kyprolis
Serious side effects reported during clinical trials included kidney insufficiency, cardiac failure, arrhythmias, abnormally high blood pressure in the arteries of the lungs, and liver failure.
Common side effects of Kyprolis
Common side effects of Kyprolis may include fatigue, anemia, nausea, low number of platelets, shortness of breath, diarrhea, fever, dizziness, fainting, or a drop in blood pressure.
You must promptly report to your doctor any changes in your health. No problem is too small to report. Be sure you know how to contact your doctor outside of office hours.
For more information about Kyprolis, use the QR code below to read the IMF’s booklet Understanding KYPROLIS® (carfilzomib) injection .
The IMF urges you to discuss all medical issues with your doctor, and to contact the IMF InfoLine with your myeloma-related questions and concerns.
tc-kypro_EN_2023_h1-05
KYPROLIS® (carfilzomib) injection
